Terms: = Uterine cancer AND FBXW7, AGO, 55294, ENSG00000109670, FLJ11071, SEL-10, CDC4, FBXW6, SEL10, FBW7, DKFZp686F23254, FBX30 AND Prognosis
37 results:
1. Moving into the modern era of molecular classification for endometrial cancer.
Dagher C; Liu YL; Mueller JJ; Weigelt B
J Surg Oncol; 2024 Jan; 129(1):120-125. PubMed ID: 38100711
[TBL] [Abstract] [Full Text] [Related]
2. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis.
Brown M; Leon A; Kedzierska K; Moore C; Belnoue-Davis HL; Flach S; Lydon JP; DeMayo FJ; Lewis A; Bosse T; Tomlinson I; Church DN
EMBO Mol Med; 2023 Oct; 15(10):e17094. PubMed ID: 37589076
[TBL] [Abstract] [Full Text] [Related]
3. Alteration of tumor suppressors changes the endometrial tumor spectrum.
Mayo LD
EMBO Mol Med; 2023 Oct; 15(10):e18166. PubMed ID: 37587857
[TBL] [Abstract] [Full Text] [Related]
4. Fortuitously detected primary ovarian carcinoid tumor: A case report.
Choi HY; Pak MG; Park JW
Medicine (Baltimore); 2023 Aug; 102(31):e34391. PubMed ID: 37543794
[TBL] [Abstract] [Full Text] [Related]
5. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
Li J; Xue X; Zhang Y; Ding F; Wu W; Liu C; Xu Y; Chen H; Ou Q; Shao Y; Li X; Wu F; Wu X
Gynecol Oncol; 2023 Aug; 175():133-141. PubMed ID: 37356314
[TBL] [Abstract] [Full Text] [Related]
6. HE4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial cancer: A Review.
Mais V; Fais ML; Peiretti M; Fanni D; Massa E; Carboni G; Fais G; Deo G; Angioni S
Curr Oncol; 2022 Nov; 29(11):8540-8555. PubMed ID: 36354733
[TBL] [Abstract] [Full Text] [Related]
7. Identification of Oxidative Stress-Associated Molecular Subtypes and Signature for Predicting Survival Outcome of Cervical Squamous Cell Carcinoma.
Wang L; Qu H; Ma X; Liu X
Oxid Med Cell Longev; 2022; 2022():1056825. PubMed ID: 36225179
[TBL] [Abstract] [Full Text] [Related]
8. Recurrent or primary metastatic cervical cancer: current and future treatments.
Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
[TBL] [Abstract] [Full Text] [Related]
9. Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance.
Kashofer K; Regauer S; Reich O; Petru E; Winter E
Gynecol Oncol; 2022 Apr; 165(1):121-128. PubMed ID: 35101299
[TBL] [Abstract] [Full Text] [Related]
10. TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer.
Kuno I; Takayanagi D; Asami Y; Murakami N; Matsuda M; Shimada Y; Hirose S; Kato MK; Komatsu M; Hamamoto R; Okuma K; Kohno T; Itami J; Yoshida H; Shiraishi K; Kato T
Sci Rep; 2021 Sep; 11(1):19261. PubMed ID: 34584128
[TBL] [Abstract] [Full Text] [Related]
11. uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract] [Full Text] [Related]
12. Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer.
Tian X; Ge D; Zhang F; Zhang B; Bai W; Xu X; Li Z; Cao Y; Li P; Zou K; Zou L
Int J Cancer; 2021 Feb; 148(4):921-931. PubMed ID: 33113150
[TBL] [Abstract] [Full Text] [Related]
13. Intravascular (post-hysterectomy) leiomyoma (IVL) as late tumor thrombus within the inferior vena cava (IVC)-A rare case primarily imposing as IVC thrombus originating from left renal vein after former left nephrectomy status.
Ghanem M; Meyer F; Jechorek D; Schoeder V; Ignatov A; Fadel M; Halloul Z
Pathol Res Pract; 2019 Jun; 215(6):152359. PubMed ID: 30853174
[TBL] [Abstract] [Full Text] [Related]
14. Quality of life in long-term survivors of early stage endometrial cancer.
Dobrzycka B; Terlikowski R; Kulesza-Brończyk B; Niklinski J; Terlikowsk SJ
Ann Agric Environ Med; 2017 Sep; 24(3):513-516. PubMed ID: 28954500
[TBL] [Abstract] [Full Text] [Related]
15. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the ago-OVAR 16 study.
Pulford DJ; Harter P; Floquet A; Barrett C; Suh DH; Friedlander M; Arranz JA; Hasegawa K; Tada H; Vuylsteke P; Mirza MR; Donadello N; Scambia G; Johnson T; Cox C; Chan JK; Imhof M; Herzog TJ; Calvert P; Wimberger P; Berton-Rigaud D; Lim MC; Elser G; Xu CF; du Bois A
BMC Med Ethics; 2016 Oct; 17(1):63. PubMed ID: 27769273
[TBL] [Abstract] [Full Text] [Related]
16. Lymphoma of the Cervix: Case Report and Review of the Literature.
Hilal Z; Hartmann F; Dogan A; Cetin C; Krentel H; Schiermeier S; Schultheis B; Tempfer CB
Anticancer Res; 2016 Sep; 36(9):4931-40. PubMed ID: 27630351
[TBL] [Abstract] [Full Text] [Related]
17. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract] [Full Text] [Related]
18. Immunohistochemical Profiling of Endometrial Serous Carcinoma.
Chen W; Husain A; Nelson GS; Rambau PF; Liu S; Lee CH; Lee S; Duggan MA; Köbel M
Int J Gynecol Pathol; 2017 Mar; 36(2):128-139. PubMed ID: 27167671
[TBL] [Abstract] [Full Text] [Related]
19. Genetic Investigation of uterine Carcinosarcoma: Case Report and Cohort Analysis.
Hembree TN; Teer JK; Hakam A; Chiappori AA
Cancer Control; 2016 Jan; 23(1):61-6. PubMed ID: 27009459
[TBL] [Abstract] [Full Text] [Related]
20. Loss of fbxw7 is related to the susceptibility and poor prognosis of cervical squamous carcinoma.
Xu Y; Yu J; Liu T; Meng F; Kong D; Lou G
Biomarkers; 2016; 21(4):379-85. PubMed ID: 26954701
[TBL] [Abstract] [Full Text] [Related]
[Next]
